Nociceptin receptor agonists - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “Nociceptin receptor agonists - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Nociceptin receptor agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Nociceptin receptor agonists: Overview
Nociceptin (also known as orphanin FQ) is a 17-amino-acid polypeptide that is structurally related to the opioid peptide dynorphin A. It is the endogenous ligand for the nociceptin opioid (NOP) receptor (formerly referred to as opioid receptor-like-1). Nociceptin does not bind to ?, ?, or ? opioid receptors, and no known exogenous or endogenous opioids bind to the NOP receptor. The neuroanatomical distribution of nociceptin and its receptor are distinct from other opioid peptides. NOP is primarily an inhibitory neuropeptide that acts on neurons to depress synaptic transmission. NOP is reported to modulate pain, stress and anxiety, feeding, learning and memory, reward and addiction, and the functioning of the heart and vessels, airways, kidney, urinary bladder, intestine, and immune cells. The broad spectrum of pharmacological effects of NOP suggests potential therapeutic applications for NOP receptor agonists and/or antagonists.
Report Highlights
This segment of the Nociceptin receptor agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nociceptin receptor agonists Emerging Drugs
Further product details are provided in the report……..
Nociceptin receptor agonists: Therapeutic Assessment
This segment of the report provides insights about the different Nociceptin receptor agonists drugs segregated based on following parameters that define the scope of the report, such as:
Nociceptin receptor agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nociceptin receptor agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nociceptin receptor agonists drugs.
Nociceptin receptor agonists Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Nociceptin receptor agonists - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Nociceptin receptor agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Nociceptin receptor agonists: Overview
Nociceptin (also known as orphanin FQ) is a 17-amino-acid polypeptide that is structurally related to the opioid peptide dynorphin A. It is the endogenous ligand for the nociceptin opioid (NOP) receptor (formerly referred to as opioid receptor-like-1). Nociceptin does not bind to ?, ?, or ? opioid receptors, and no known exogenous or endogenous opioids bind to the NOP receptor. The neuroanatomical distribution of nociceptin and its receptor are distinct from other opioid peptides. NOP is primarily an inhibitory neuropeptide that acts on neurons to depress synaptic transmission. NOP is reported to modulate pain, stress and anxiety, feeding, learning and memory, reward and addiction, and the functioning of the heart and vessels, airways, kidney, urinary bladder, intestine, and immune cells. The broad spectrum of pharmacological effects of NOP suggests potential therapeutic applications for NOP receptor agonists and/or antagonists.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Nociceptin receptor agonists R&D. The therapies under development are focused on novel approaches for Nociceptin receptor agonists.
This segment of the Nociceptin receptor agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nociceptin receptor agonists Emerging Drugs
- IMB-115: Imbrium Therapeutics
- Buvidal: Camurus
Further product details are provided in the report……..
Nociceptin receptor agonists: Therapeutic Assessment
This segment of the report provides insights about the different Nociceptin receptor agonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Nociceptin receptor agonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Nociceptin receptor agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nociceptin receptor agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nociceptin receptor agonists drugs.
Nociceptin receptor agonists Report Insights
- Nociceptin receptor agonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Nociceptin receptor agonists drugs?
- How many Nociceptin receptor agonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nociceptin receptor agonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Nociceptin receptor agonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Nociceptin receptor agonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Imbrium Therapeutics
- Camurus
- INSYS Therapeutics
- Alkermes
- Aoxing Pharmaceutical Company
- Tris Pharma
- Chiesi Farmaceutici
- Alar Pharmaceuticals
- iX Biopharma
- Grunenthal
- Lyndra Therapeutics
- Zealand Pharma
- Faran Shirin
- IMB-115
- Buvidal
- Buprenorphine sublingual
- ALKS 33-BUP
- Naloxone/buprenorphine
- PRK-101
- ALA-1000
- BnoX
- Nociceptin/orphanin FQ peptide receptor agonist therapeutic
- LYN-013
- ZP-120
Introduction
Executive Summary
Nociceptin receptor agonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Nociceptin receptor agonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Buvidal: Camurus
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
IMB-115: Imbrium Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Buprenorphine - iX Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Nociceptin receptor agonists Key Companies
Nociceptin receptor agonists Key Products
Nociceptin receptor agonists- Unmet Needs
Nociceptin receptor agonists- Market Drivers and Barriers
Nociceptin receptor agonists- Future Perspectives and Conclusion
Nociceptin receptor agonists Analyst Views
Nociceptin receptor agonists Key Companies
Appendix
Executive Summary
Nociceptin receptor agonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Nociceptin receptor agonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Buvidal: Camurus
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
IMB-115: Imbrium Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Buprenorphine - iX Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Nociceptin receptor agonists Key Companies
Nociceptin receptor agonists Key Products
Nociceptin receptor agonists- Unmet Needs
Nociceptin receptor agonists- Market Drivers and Barriers
Nociceptin receptor agonists- Future Perspectives and Conclusion
Nociceptin receptor agonists Analyst Views
Nociceptin receptor agonists Key Companies
Appendix